JP2023503470A5 - - Google Patents

Info

Publication number
JP2023503470A5
JP2023503470A5 JP2022530701A JP2022530701A JP2023503470A5 JP 2023503470 A5 JP2023503470 A5 JP 2023503470A5 JP 2022530701 A JP2022530701 A JP 2022530701A JP 2022530701 A JP2022530701 A JP 2022530701A JP 2023503470 A5 JP2023503470 A5 JP 2023503470A5
Authority
JP
Japan
Prior art keywords
alkyl
membered
heteroaryl
aryl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022530701A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023503470A (ja
JP7890737B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/061156 external-priority patent/WO2021105906A1/en
Publication of JP2023503470A publication Critical patent/JP2023503470A/ja
Publication of JP2023503470A5 publication Critical patent/JP2023503470A5/ja
Application granted granted Critical
Publication of JP7890737B2 publication Critical patent/JP7890737B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022530701A 2019-11-25 2020-11-25 ガラクトセレブロシダーゼの活性の変質に関連する状態におけるアリールおよびヘテロアリール化合物、ならびにそれらの治療的使用 Active JP7890737B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19383036 2019-11-25
EP19383036.1 2019-11-25
PCT/IB2020/061156 WO2021105906A1 (en) 2019-11-25 2020-11-25 Aryl and heteroaryl compounds, and therapeutic uses thereof in conditions associated with the alteration of the activity of galactocerebrosidase

Publications (3)

Publication Number Publication Date
JP2023503470A JP2023503470A (ja) 2023-01-30
JP2023503470A5 true JP2023503470A5 (cg-RX-API-DMAC10.html) 2023-11-24
JP7890737B2 JP7890737B2 (ja) 2026-07-15

Family

ID=68808238

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022530701A Active JP7890737B2 (ja) 2019-11-25 2020-11-25 ガラクトセレブロシダーゼの活性の変質に関連する状態におけるアリールおよびヘテロアリール化合物、ならびにそれらの治療的使用

Country Status (11)

Country Link
US (1) US20230058312A1 (cg-RX-API-DMAC10.html)
EP (1) EP4065546A1 (cg-RX-API-DMAC10.html)
JP (1) JP7890737B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220150880A (cg-RX-API-DMAC10.html)
CN (1) CN115397806A (cg-RX-API-DMAC10.html)
AU (1) AU2020393174A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022010127A2 (cg-RX-API-DMAC10.html)
CA (1) CA3158290A1 (cg-RX-API-DMAC10.html)
IL (1) IL293409A (cg-RX-API-DMAC10.html)
MX (1) MX2022006059A (cg-RX-API-DMAC10.html)
WO (1) WO2021105906A1 (cg-RX-API-DMAC10.html)

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500714A (en) * 1981-10-15 1985-02-19 Chugai Seiyaku Kabushiki Kaisha 3-Substituted-ureido-N-pyridyl benzamides
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
EP1615931A1 (en) 2003-04-09 2006-01-18 Biogen Idec MA Inc. Triazolopyrazines and methods of making and using the same
EP1644334B1 (en) * 2003-05-30 2008-01-02 Eli Lilly and Company Antithrombotic ethers
US7511066B2 (en) * 2003-09-30 2009-03-31 Eli Lilly And Company Antithrombotic aromatic ethers
WO2005085188A2 (en) * 2004-03-02 2005-09-15 Compass Pharmaceuticals Llc Compounds and methods for anti-tumor therapy
SE0401345D0 (sv) * 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds: Pyridine as scaffold
SE0401343D0 (sv) * 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds: Pyridine N oxide as scaffold
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
ES2580108T3 (es) * 2005-07-11 2016-08-19 Aerie Pharmaceuticals, Inc Compuestos de isoquinolina
PT2404919E (pt) 2005-11-08 2013-10-22 Vertex Pharma Composto heterocíclico útil como um modulador de transportadores de cassete de ligação a atp
EP2016065B1 (en) 2005-12-28 2012-09-19 Vertex Pharmaceuticals Incorporated 1-(benzo[d][1,3]dioxol-5-yl)-n-(phenyl)cyclopropane-carboxamide derivatives and related compounds as modulators of atp-binding cassette transporters for the treatment of cystic fibrosis
US8399448B2 (en) 2007-08-08 2013-03-19 Merck Serono Sa 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (S1P) receptor for the treatment of multiple sclerosis
EP2307440A4 (en) 2008-07-01 2012-12-19 Zacharon Pharmaceuticals Inc HEPARAN SULFATE INHIBITORS
US20120100609A1 (en) * 2009-03-27 2012-04-26 Crawford Brett E N-linked glycan biosynthesis modulators
WO2011049737A1 (en) 2009-10-19 2011-04-28 Amicus Therapeutics, Inc. Novel compositions for preventing and/or treating lysosomal storage disorders
PL3366688T3 (pl) 2010-12-08 2022-05-23 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Podstawione pirazolopirymidyny jako aktywatory glukocerebrozydazy
KR20130131461A (ko) 2011-03-07 2013-12-03 폰다지오네 텔레톤 Tfeb 변종 및 그의 용도
LT2685986T (lt) 2011-03-18 2020-03-10 Genzyme Corporation Gliukozilceramido sintazės slopiklis
WO2013078413A1 (en) * 2011-11-22 2013-05-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulators of lipid storage
JP2017511340A (ja) * 2014-03-31 2017-04-20 ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク ヒストンアセチルトランスフェラーゼ活性剤及びその使用
WO2017026516A1 (ja) 2015-08-12 2017-02-16 持田製薬株式会社 イソチアゾール誘導体
WO2017040971A1 (en) 2015-09-03 2017-03-09 Biomarin Pharmaceutical Inc. Methods of using inhibitors of pikfyve for the treatment of lysosomal storage disorders and neurodegenerative diseases
US9938273B2 (en) * 2015-12-07 2018-04-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US10160747B2 (en) * 2016-03-16 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
MX2019000864A (es) * 2016-07-20 2019-06-03 Univ Columbia Activadores de histona acetiltransferasa y sus composiciones y usos.

Similar Documents

Publication Publication Date Title
KR100797603B1 (ko) 섬유근육통을 치료하기 위한 도파민 d2/d3 수용체작용제의 사용
TWI511728B (zh) 包含非典型抗精神病藥物及taar1激動劑之醫藥組合
US20190343817A1 (en) Method of treating pain
RU2004117887A (ru) Ариланилиновые агонисты бета2 адренергических рецепторов
JP2005509024A5 (cg-RX-API-DMAC10.html)
AU2009273259B2 (en) Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation
ES2350103T3 (es) Asociación de un antagonista o agonista inverso del receptor h3 de la histamina con un antipsicótico o un antidepresivo y su uso para preparar un medicamento que evite los efectos indeseables de los fármacos psicotropos.
CA3227602A1 (en) Inhibitors for coronaviruses
JP2023544716A5 (cg-RX-API-DMAC10.html)
JP2023503465A5 (cg-RX-API-DMAC10.html)
JP2018203774A (ja) 精神障害の治療における使用のためのイロペリドン代謝物
JP2005532397A5 (cg-RX-API-DMAC10.html)
ZA200106439B (en) Use of polycyclic thiazole systems for producing medicaments for preventing or treating obesity.
HUP0204282A2 (hu) Biszszulfonamidok alkalmazása hiperlipidémia kezelésére vagy megelőzésére alkalmas gyógyászati készítmények előállítására
US9126989B2 (en) Compound and methods for treating long QT syndrome
MX2007012070A (es) Tratamiento de la epilepsia con ligandos del receptor h3 de histamina, tipo alquilaminas no imidazol.
US5116839A (en) Use of isoxazolin-3-one derivatives as antidepressants
JPH01242574A (ja) 含窒素縮合環を有するピペリジン及びピペラジン誘導体、その製造方法並びにそれを含む薬学的組成物
JP2004538292A (ja) ナトリウム・カルシウム交換系を阻害する医薬
JPS6132287B2 (cg-RX-API-DMAC10.html)
EP1757593A1 (en) Therapeutic agent for nonviral hepatitis
HK40111722A (en) Inhibitors for coronaviruses
RU2339627C2 (ru) Новые арилпиперазиниловые соединения
JPH10109936A (ja) 糖尿病性神経障害の治療・予防剤
HK1155096B (en) Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation